Get started
Author

Eduardo Patricio Yanez Ruiz

Observed names: E.P. Yanez Ruiz, E.P.Y. Ruiz, Eduardo P. Yanez Ruiz, Eduardo P. Yañez Ruiz
Observed institution: Universidad de La Frontera
OpenAlex ID: A5114227210
Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer
2016 · Hope S. Rugo, Abhijit Barve, et al. · JAMA · 146
PDF
Subcutaneous versus intravenous nivolumab for renal cell carcinoma
2024 · L. Albiges, M.T. Bourlon, et al. · Annals of Oncology · 31
A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1).
2019 · Manish A. Shah, Eduardo Patricio Yanez Ruiz, et al. · Journal of Clinical Oncology · 28
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)
2021 · Dmytro Trukhin, Elena Poddubskaya, et al. · BioDrugs · 27
PDF
Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin.
2016 · Hope S. Rugo, Abhijit Barve, et al. · Journal of Clinical Oncology · 19
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
2021 · Hope S. Rugo, Eduardo J. Pennella, et al. · Breast Cancer Research and Treatment · 14
PDF
Heritage, a phase III safety and efficacy trial of the proposed trastuzumab biosimilar, Myl-1401O vs trastuzumab
2016 · H. Rugo, A. Barve, et al. · Annals of Oncology · 8
Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial
2021 · Hope S. Rugo, Eduardo J. Pennella, et al. · The Breast · 6
PDF
Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin.
2016 · Hope S. Rugo, Abhijit Barve, et al. · Journal of Clinical Oncology · 6
Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T.
2024 · Saby George, Maria Teresa Bourlon, et al. · Journal of Clinical Oncology · 5
HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus herceptin
2017 · H. Rugo, A. Barve, et al. · European Journal of Cancer · 4
855P Safety and efficacy of vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in previously untreated advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II KEYVIBE-005 study
2024 · C. Toullec, S. Seo, et al. · Annals of Oncology · 3
21O Coformulated vibostolimab/pembrolizumab in advanced cervical cancer: KEYVIBE-005
2024 · A. Leary, K. Yonemori, et al. · ESMO Open · 3
PDF
Subcutaneous (SC) nivolumab (NIVO) vs intravenous (IV) NIVO in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Safety and patient-reported outcomes (PROs) of the randomized phase 3 CheckMate 67T trial.
2024 · Maria T. Bourlon, Laurence Albiges, et al. · Journal of Clinical Oncology · 3
22O Association of biomarkers with response to coformulated vibostolimab/pembrolizumab (vibo/pembro) in metastatic cervical cancer (CC): Exploratory analysis from the phase II KEYVIBE-005 study
2024 · C. Le Tourneau, C.I. Rojas, et al. · ESMO Open · 2
652P 3-year follow-up of a phase III study to compare efficacy and safety of a bevacizumab biosimilar, CT-P16, and reference bevacizumab as first-line treatment for metastatic or recurrent non-squamous non-small cell lung cancer
2024 · C. Verschraegen, Z.G. Andric, et al. · Annals of Oncology · 1
PDF
1691P Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients (pts) with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Updated efficacy and safety results from CheckMate 67T
2024 · L. Albiges, M.T. Bourlon de los Rios, et al. · Annals of Oncology
PDF
25P Patient-reported outcomes (PROs) with coformulated vibostolimab/pembrolizumab (vibo/pembro) for metastatic cervical cancer (CC): Results from the KEYVIBE-005 study
2024 · K. Yonemori, C.I. Rojas, et al. · ESMO Open
PDF
Works count: 18
Citation count: 306
H-index: 7
I10-index: 6
Year
Topic
Type